Conidia Bioscience Ltd has been trading since 2002. The organisation spun out from the not for profit, international intergovernmental research and publishing organisation, CABI to exploit the commercial potential of its Technical Director’s invention.
Conidia’s internationally patented intellectual property, based on immunoassay technology, was first presented in the form of a rapid fuel test for jet fuel fungus for the aviation industry. Its adoption was rapid given the highly regulated and conservative nature of the industry. The product’s credibility is enhanced by IATA recommendation and inclusion in the Boeing, Airbus, Embraer, BAE Systems, Fokker and Raytheon maintenance manuals. The kit is currently regularly purchased by 300+ airlines and aircraft maintenance organisations around the world. Sales are still growing rapidly, with an increase of 40% in 2010.
As a major shareholder, CABI shares its extensive facilities with Conidia Bioscience Ltd, including its impressively resourced, UKAS accredited laboratory facility. Dr Joan Kelley, inventor and Technical Director of both CABI and Conidia, manages and orchestrates the extensive Conidia Bioscience R&D programme.
Other Conidia Bioscience shareholders include two corporate investors and an Austrian life science strategic partner, Biomedica Group, which is actively involved in Conidia Bioscience's R&D and production.